Table 1.
Predictive factors for complete pathological response in univariate logistic regression analysis for all patients
| Variable | Non-pCR (n = 331) n P50 (P25-P75) | pCR (n = 72) n P50 (P25-P75) | pCR rate | P-value | |
| Gender | Male | 232 | 49 | 17.44% | 0.653 |
| Female | 96 | 23 | 19.33% | ||
| Age (yr) | ≤ 60 | 210 | 54 | 20.45% | 0.07 |
| > 60 | 119 | 18 | 13.14% | ||
| BMI (kg/cm2) | < 25 | 231 | 53 | 18.66% | 0.581 |
| ≥ 25 | 78 | 15 | 16.13% | ||
| Hemoglobin (g/L) | ≤ 125 | 109 | 16 | 12.80% | 0.126 |
| > 125 | 172 | 41 | 19.25% | ||
| NLR | > 3 | 37 | 11 | 22.92% | 0.227 |
| ≤ 3 | 244 | 46 | 15.86% | ||
| Platelet (× 109/L) | 237.5 (200.25-286.75) | 246 (200.5-268.5) | 0.981 | ||
| ApoA1 (g/L) | 1.29 (1.13-1.44) | 1.3 (1.15-1.52) | 0.454 | ||
| ApoB (g/L) | 0.98 (0.79-1.14) | 0.97 (0.82-1.19) | 0.382 | ||
| The interval (d) | 39 (22.25-54) | 50 (42-56.5) | 0 | ||
| CEA (ng/mL) | > 5 | 163 | 28 | 14.66% | 0.217 |
| ≤ 5 | 118 | 29 | 19.73% | ||
| Differentiation | Moderate-poor | 274 | 44 | 13.84% | 0.001 |
| Well | 44 | 20 | 31.25% | ||
| DTAV (cm) | < 5 | 140 | 41 | 22.65% | 0.024 |
| ≥ 5 | 191 | 31 | 13.96% | ||
| TL (cm) | > 3 | 237 | 41 | 14.75% | 0.001 |
| ≤ 3 | 73 | 30 | 29.13% | ||
| TCE | < 50% | 37 | 7 | 15.91% | 0.772 |
| ≥ 50% | 256 | 55 | 17.68% | ||
| cT | 2 | 16 | 5 | 23.81% | 0.405 |
| 3 | 234 | 56 | 19.31% | ||
| 4 | 54 | 8 | 12.90% | ||
| cN | + | 235 | 57 | 19.52% | 0.465 |
| - | 78 | 15 | 16.13% | ||
| MRF | - | 231 | 61 | 20.89% | 0.013 |
| + | 97 | 11 | 10.19% | ||
| NT regimen | Capecitabine/de Gramont-RT | 102 | 13 | 11.30% | 0 |
| mFOLFOX6 | 148 | 14 | 8.64% | ||
| mFOLFOX6-RT | 81 | 45 | 35.71% | ||
Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.